Pharmsville Co., Ltd. (KOSDAQ:318010)
South Korea · Delayed Price · Currency is KRW 3,575.00
+10.00 (0.28%)
At close: May 29, 2026
Pharmsville Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | - | - | -0 | -0 | - | - |
| 11,877 | 12,728 | 16,725 | 21,395 | 26,113 | 39,028 | |
Revenue Growth (YoY) | -22.22% | -23.90% | -21.83% | -18.07% | -33.09% | -0.97% |
Cost of Revenue | 4,377 | 4,683 | 6,224 | 8,253 | 10,290 | 13,266 |
Gross Profit | 7,500 | 8,045 | 10,501 | 13,142 | 15,823 | 25,762 |
Selling, General & Admin | 6,237 | 6,617 | 9,051 | 9,071 | 9,811 | 18,147 |
Research & Development | 1,874 | 1,882 | 1,482 | 2,187 | 1,661 | 1,189 |
Amortization of Goodwill & Intangibles | 25.51 | 24.23 | 19.99 | 20.25 | 20.89 | 36.27 |
Other Operating Expenses | 95.49 | 100.4 | 136.39 | 119.08 | 169.11 | 108.1 |
Operating Expenses | 8,324 | 8,721 | 10,771 | 11,499 | 11,761 | 19,614 |
Operating Income | -823.88 | -675.66 | -269.85 | 1,643 | 4,063 | 6,147 |
Interest Expense | -0.83 | -0.89 | -44.27 | -150.37 | -152.86 | -74.18 |
Interest & Investment Income | 116.87 | 177.19 | 484.17 | 798.35 | 839.1 | 413.13 |
Earnings From Equity Investments | - | - | - | -63.31 | - | - |
Currency Exchange Gain (Loss) | 0.35 | -17.69 | 30.03 | 1.65 | 13.09 | 15.67 |
Other Non Operating Income (Expenses) | 1,351 | 1,297 | 1,214 | 1,368 | 846.73 | 465.41 |
EBT Excluding Unusual Items | 643.76 | 780.26 | 1,415 | 3,597 | 5,609 | 6,968 |
Gain (Loss) on Sale of Investments | 3,121 | 2,810 | 415.33 | 403.42 | -458.66 | -803.26 |
Gain (Loss) on Sale of Assets | - | - | - | -33.82 | 41.82 | - |
Pretax Income | 3,764 | 3,591 | 1,830 | 3,966 | 5,192 | 6,164 |
Income Tax Expense | 752.9 | 688.26 | 246.71 | 659.32 | 1,128 | 1,168 |
Earnings From Continuing Operations | 3,012 | 2,902 | 1,583 | 3,307 | 4,064 | 4,996 |
Minority Interest in Earnings | -22.9 | -13.89 | -0.1 | 2.42 | -0.74 | 3.53 |
Net Income | 2,989 | 2,889 | 1,583 | 3,310 | 4,063 | 5,000 |
Net Income to Common | 2,989 | 2,889 | 1,583 | 3,310 | 4,063 | 5,000 |
Net Income Growth | 60.62% | 82.47% | -52.17% | -18.54% | -18.74% | 72.92% |
Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 | 8 |
Shares Change (YoY) | 0.08% | 0.08% | -1.40% | -0.19% | - | -0.29% |
EPS (Basic) | 386.75 | 373.77 | 205.00 | 422.59 | 517.79 | 637.23 |
EPS (Diluted) | 386.75 | 373.77 | 205.00 | 422.59 | 517.79 | 637.00 |
EPS Growth | 60.49% | 82.33% | -51.49% | -18.38% | -18.71% | 73.57% |
Free Cash Flow | 1,517 | 1,891 | -372.74 | 4,450 | 5,083 | 7,982 |
Free Cash Flow Per Share | 196.32 | 244.68 | -48.27 | 568.20 | 647.87 | 1017.25 |
Dividend Per Share | - | - | - | 100.000 | 100.000 | 100.000 |
Gross Margin | 63.15% | 63.21% | 62.79% | 61.43% | 60.59% | 66.01% |
Operating Margin | -6.94% | -5.31% | -1.61% | 7.68% | 15.56% | 15.75% |
Profit Margin | 25.16% | 22.69% | 9.46% | 15.47% | 15.56% | 12.81% |
Free Cash Flow Margin | 12.77% | 14.86% | -2.23% | 20.80% | 19.47% | 20.45% |
EBITDA | -227.89 | -34.92 | 405.04 | 2,319 | 4,734 | 6,364 |
EBITDA Margin | -1.92% | -0.27% | 2.42% | 10.84% | 18.13% | 16.31% |
D&A For EBITDA | 595.99 | 640.74 | 674.9 | 675.99 | 671.39 | 216.32 |
EBIT | -823.88 | -675.66 | -269.85 | 1,643 | 4,063 | 6,147 |
EBIT Margin | -6.94% | -5.31% | -1.61% | 7.68% | 15.56% | 15.75% |
Effective Tax Rate | 20.00% | 19.17% | 13.48% | 16.62% | 21.73% | 18.95% |
Advertising Expenses | - | 1,005 | 1,727 | 865.93 | 843.02 | 3,230 |